Literature DB >> 18454096

[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].

A A Zozulia, G G Neznamov, T S Siuniakov, N V Kost, M V Gabaeva, O Iu Sokolov, E V Serebriakova, O A Siranchieva, A V Andriushenko, E S Telesheva, S A Siuniakov, A B Smulevich, N F Miasoedov, S B Seredenin.   

Abstract

Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied. The effect of selank (30 patients) was compared to that of medazepam (32 patients). Patient's state was assessed with psychometric scales (Hamilton, Zung, CGI). Enkephalin activity in the blood serum was measured as well. The anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects. The clinical-biological study revealed that patients with GAD and neurasthenia had the decreased level of tau(1/2) leu-enkephalin which was correlated with disease duration, severity of symptoms related to anxiety and asthenia and autonomic disorders. The increase of this parameter and stronger positive correlations with anxiety level were observed during the treatment with selank mostly in patients with GAD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18454096

Source DB:  PubMed          Journal:  Zh Nevrol Psikhiatr Im S S Korsakova        ISSN: 1997-7298


  2 in total

1.  The influence of oligopeptides on spontaneous carcinogenesis in mice.

Authors:  V K Meshavkin; N V Kost; O Yu Sokolov; L A Andreeva; N F Myasoedov
Journal:  Dokl Biol Sci       Date:  2013-05-08

2.  Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.

Authors:  Anastasiya Kasian; Timur Kolomin; Lyudmila Andreeva; Elena Bondarenko; Nikolay Myasoedov; Petr Slominsky; Maria Shadrina
Journal:  Behav Neurol       Date:  2017-02-09       Impact factor: 3.342

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.